RxDoctor Payments Data

Robert Axonovitz, MD

Internal Medicine · Sylvania, OHNPI 1730180407

Payments from drug & device makers

$5,634in general payments, 2019–2025

Across 299 payments — averaging $18.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • AstraZeneca$973
  • Boehringer Ingelheim$574
  • AbbVie$543
  • Pfizer$513
  • Novo Nordisk$426
  • plus $2K from 29 others

What the payments were for

  • Food & beverage$5,621100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,634 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$115,886
Medicare patients
156
Services billed
4,558

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban98$102,675
OzempicSemaglutide52$61,808
XareltoRivaroxaban17$21,032
Repatha SureclickEvolocumab12$19,014
FarxigaDapagliflozin Propanediol21$15,811
LinzessLinaclotide24$10,997
TrulicityDulaglutide11$10,581
Buprenorphine12$4,647
Pitavastatin Calcium24$3,314
Atorvastatin Calcium327$3,287
PaxlovidNirmatrelvir/Ritonavir27$2,858
Metoprolol Succinate143$2,025
Olmesartan Medoxomil103$1,976
Pantoprazole Sodium118$1,630
Levothyroxine Sodium170$1,364

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$513$105,534125 claims
Novo NordiskOzempic$426$61,80852 claims
Johnson & JohnsonXarelto$180$21,03217 claims
AstraZenecaFarxiga$973$15,81121 claims
AbbVieLinzess, Synthroid$543$11,77550 claims
Lilly USA, LLCTrulicity$16$10,58111 claims
Almatica Pharma LLCSertraline Hcl$14$536102 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Sylvania

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →